OSR Health CEO Peter Hwang reaffirmed confidence in the company's fundamental value and disclosed that two subsidiaries have received inbound inquiries for potential out-licensing of their technologies and products, with one at the preliminary term sheet negotiation phase and the other in early-stage discussions. The announcement comes as the company faces an August 18 deadline for Nasdaq to determine its continued listing status if the stock price has not regained the $1.00 minimum bid requirement. Hwang stated he remains 'all in' as the largest investor, having committed substantial personal capital since inception, and believes the accelerating business development activities will increasingly demonstrate commercial potential. He asked shareholders to remain engaged and supportive during this critical period, emphasizing that the company is doing everything within its control to preserve its Nasdaq listing.
OSR Holdings IncCEO reaffirms confidence and discloses out-licensing talks, supporting fundamental value amid Nasdaq listing risk.
